pharma · Hypoparathyroidism · Postbariatric Hypoglycemia · MBX
MBX Biosciences
MBX Biosciences is a pharma organization headquartered in Carmel, USA. It trades on NYSE under ticker MBX. Primary therapeutic focus areas include Hypoparathyroidism, Postbariatric Hypoglycemia, Renal Impairment, Obesity
Company details
- Status
- Public
- HQ
- Carmel, USA
- Founded
- 2019
- Employees
- 74
- Programs
- 7
- Drugs
- 3
- Patents
- 0
Quick answer
MBX Biosciences is a pharma organization headquartered in Carmel, USA. It trades on NYSE under ticker MBX. Primary therapeutic focus areas include Hypoparathyroidism, Postbariatric Hypoglycemia, Renal Impairment, Obesity. NovaPharmaNews links 7 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 1 (4), phase 2 (3).
Company snapshot
MBX Biosciences, Inc. is a clinical stage biopharmaceutical company pioneering investigational Precision Endocrine Peptides (PEPs™). PEPs are designed to overcome key limitations of native peptide therapeutics to deliver superior pharmacologic properties. MBX is advancing a pipeline of PEP candidates to address the unmet needs of people with endocrine disorders. The company’s lead product candidat
- 7 active pipeline program(s) linked via ClinicalTrials.gov.
- 7 trial update(s) in the last 12 months.
Public regulatory, clinical, patent, and corporate records for MBX Biosciences. Not investment advice.
Catalysts
Upcoming readouts, regulatory dates, and congress activity.
- approval
Ten-Year-Old Cambridge Biotech Seeks Merger or Acquisition Amidst Market Pressures
Recent coverage
Top assets
Lead pipeline drugs
- approved
- Marketed / approved
- Marketed / approved
- Phase 2
Active clinical programs
- Phase 2
- Phase 2
- Phase 2
- Phase 1
Momentum
Proprietary activity score for MBX Biosciences.
2 active signals
Signal breakdown
- Clinical trials
- Nova articles
- Patents filed
- FDA actions
- SEC filings
- Conference presentations
- Pipeline advances
Recent activity
Latest pipeline, patent, and corporate events for MBX Biosciences.
- Clinical update
400 µg of MBX 2109 once-weekly by subcutaneous injection — Phase 2
- Partnership signal
Ten-Year-Old Cambridge Biotech Seeks Merger or Acquisition Amidst Market Pressures
- Clinical update
- Clinical update
- Clinical update
Quick answers
Common questions about this sponsor — for analysts and search.
-
What is MBX Biosciences?
-
Is MBX Biosciences publicly traded?
-
What drugs does MBX Biosciences develop or market?
-
What are the latest developments for MBX Biosciences?
-
What therapeutic areas does MBX Biosciences focus on?
Therapeutic focus
Therapeutic area distribution
Pipeline concentration by therapeutic area from linked clinical programs.